When Japanese pharmaceutical company Daiichi Sankyo Co. discovered a groundbreaking cancer treatment, it turned to bigger Western drugmaker AstraZeneca Plc. to help commercialize the therapy that ...

AstraZeneca PLC AZN and partner Merck MRK announced that the Japanese Ministry of Health, Labour, and Welfare has approved their PARP inhibitor, Lynparza for an early-stage breast cancer indication.

TOKYO (MarketWatch) -- AstraZeneca Plc AZN aims to further accelerate efforts to bring its drugs to the Japanese market by investing more and expanding clinical studies, company executives said ...

AstraZeneca has raised its bet on Japan's drug market by buying out the remaining stake held by Sumitomo Chemical in its Japanese unit AstraZeneca K.K. The British group said on Wednesday the ...

BridgeBio Pharma is behind the push to bring acoramidis to market in the U.S., but AstraZeneca holds the Japanese rights. Now, AstraZeneca has shared an update on the open-label phase 3 trial ...

Beyfortus (nirsevimab), a single-dose monoclonal antibody developed and commercialized in partnership by AstraZeneca (NASDAQ:AZN) and Sanofi (NASDAQ:SNY), has been approved in Japan for the ...

(RTTNews) - AstraZeneca (AZN.L, AZN) said that the Japanese Ministry of Health, Labour and Welfare approved Koselugo (selumetinib) for the treatment of paediatric patients three years of age and ...

The Japanese Ministry of Health, Labour and Welfare (MHLW) approved AstraZeneca's (NASDAQ:AZN) Calquence (acalabrutinib) to treat adult patients with treatment-naïve chronic lymphocytic leukemia ...

Three new cancer drugs could help AstraZeneca make a dent in its lofty ambition to become an $80 billion company by 2030.

The EC has granted approval for a fixed-duration regimen of AstraZeneca's Calquence (acalabrutinib) plus venetoclax.